November 17, 2026

00:38:38

Distal Radius Fractures As Markers of Bone Fragility

Hosted by

Antonia Chen, MD Andrew Schoenfeld, MD Ayesha Abdeen, MD
Distal Radius Fractures As Markers of Bone Fragility
Your Case Is On Hold
Distal Radius Fractures As Markers of Bone Fragility

Nov 17 2026 | 00:38:38

/

Show Notes

In this episode, Ayesha and Andrew discuss the November 18, 2026 issue of JBJS, along with an added dose of entertainment and pop culture. Listen at the gym, on your commute, or whenever your case is on hold!

Link:

JBJS website: https://jbjs.org/issue.php

Sponsor:

This episode is brought to you by JBJS Clinical Classroom.

Subspecialties:

Trauma, Hip, Pain Management, Orthopaedic Essentials, Oncology

Chapters

  • (00:00:02) - Introduction and Episode Overview
  • (00:01:09) - Table of Contents: Fracture Care in Older Patients Issue
  • (00:03:16) - Capacity-Related Delays to Hip Fracture Surgery and Mortality
  • (00:04:58) - Study Methodology and Design Details
  • (00:08:25) - Results: Mortality and Frailty Findings
  • (00:11:13) - Liposomal Bupivacaine in Geriatric Hip Fracture Surgery
  • (00:14:05) - Study Limitations and Generalizability Discussion
  • (00:17:09) - Philosophical Reflections on RCT Design and Pain Measurement
  • (00:21:28) - Cases on Hold: Distal Radius Fracture as Bone Fragility Marker
  • (00:25:55) - Critique of Control Group and Study Design Flaws
  • (00:27:23) - Debate on Frailty Proxy and Comparison Validity
  • (00:32:57) - Case Placed On Hold - Final Verdict
  • (00:33:26) - Honorable Mention: Edema Enhanced CT for Sacral Fractures
  • (00:35:55) - Honorable Mention: Intraoperative Bone Quality Assessment Study
  • (00:38:14) - Episode Wrap-up and Closing Remarks
View Full Transcript

Episode Transcript

[00:00:02] Speaker A: Welcome to your Cases on Hold, the JVGS podcast, hosted by Andrew Schoenfeld and Aisha Adkeen. [00:00:08] Speaker B: Here we discuss the best of what each issue of JBJS has to offer with the usual dose of entertainment and pop culture. [00:00:16] Speaker A: Take us with you in the gym, on the commute, and as ever, whenever your case is on hold. [00:00:26] Speaker B: Welcome back for episode number 118 of youf Case Is on Hold. If you are listening, on the day we drop it is November 17th for the November 18th issue of JBJS. It's about a week to Turkey Day and I am grateful for the opportunity to bring you all hot off the press articles for this special issue on Fracture Care in an aging population My name is Aisha Abdeen, Associate Editor for JBJS Reviews, and I have with me my co host. [00:00:51] Speaker C: I'm Andrew Schoenfeld, Associate Editor for Statistics. [00:00:56] Speaker B: And so for today I want to remind you that our ideas are those of ours alone and not of those of the Editorial Board of jbjs, for the Board of Directors, nor the affiliate journals of jbjs. This podcast is brought to you today by the JBGS Clinical Classroom for Clinical Practice, Lifelong Learning, Exam prep and Continuing Education from Med School to Practice. So we will start at the top of the pile. Today we have Fracture Care in older individuals by Dr. Okiki. It is permanently free. This article sets the stage for this special issue, the theme of which is how we can improve fracture care in older patients. The issue starts with many non scientific articles with viewpoints, a work report, expert review and health care recommendations written by leaders in the field of osteoporosis and fracture care around the world. Dr. Okiki in this article highlights three important themes of the issue, including a trend toward more arthroplasty and less fixation in the older population and the recognition that the orthopedic surgeon is the custodian of musculoskeletal health and should bear the responsibility of fracture prevention and the third team of there being a gap about how we currently care for patients and what is actually the optimal treatment for patients. Next we have Non Operative Management Deserves Consideration for Select patients with Valgus Impacted Femoral Neck Fractures by Bishop beyond the Fracture Clinic Three Things a Surgeon can do to Help Older Patients Stay out of the Hospital by Zbird High Energy Skeletal Trauma in Older Adults Best Care When We All Work Together by Switzer Movement Manners by Felder Spiel It's Permanently Free the current landscape of fragility fracture care in the People's Republic of China By Wang. It is permanently free. Prevention of periprosthetic fractures. What should we be doing to address this impending epidemic? By Lam. Global perspectives on the care gap in fragility fracture management. Bridging evidence in clinical practice by Tabu. And there's a highlight. The management of pelvic and vertebral fragility fractures. An unmet care need by Anderson. Bridging the global implementation gap and immediate weight bearing after hip fracture surgery. The weight free consensus for low adoption regions by mao. Without any further ado, we'll get to our headlines. First we have Dr. Schoenfeld presenting the effects of capacity related delay to hip fracture surgery on mortality. A matched cohort study by King. There is a commentary, so you don't have to take it from us. And it is permanently free. [00:03:29] Speaker C: Yes. So this is a very interesting study, really well done methodologically and some really important insights. I think so Overall, spoiler alert. I can say I liked it, definitely. So the work is done from the uk, comes out of the UK and the premise for the work is that there can be of course in this population medical causes of delays in surgical management due to comorbidity, need for optimization or putative clearance. Then there's also the capacity related causes which reflect inadequate operating theater or surgeons not available is doing something else. Prior work has really focused on the impacts of delays on mortality, but rarely made the distinction between patients who are delayed for medical reasons and those who are delayed for capacity reasons. Of course, in today's day and age, services must manage both the base level medical management and then also if there are patients who are waiting for fracture care, delaying that care can result in complications and downstream effects. So when there is scarcity, how do we prioritize the individuals who should go first? Not really a first come, first serve. It's about minimizing disparate impact essentially. So the authors wanted to look at this in a very elegant way, I think, assessing the effect of capacity related delays to hip fracture surgery on near term 30 day and then one year mortality. And then they also wanted to look at the effects of capacity related operative delay on institutional resource utilization and then to also identify identify patients disproportionately affected by operative delay. I applaud the authors in not doing kind of the salami slicing where they are trying to address sort of everything under the umbrella of this 1:2700 word manuscript. But I will say it's a lot to pack in there and if I had to have like one kind of like, you know what's my critique for this. I think they tried to do too much in just one. One particular item. The study involved patients presenting with a hip fracture of the native proximal femur at a UK teaching hospital between 2020 and 2024, with surveillance extended through October 2025. And they are looking for delays and the reasons for delays beyond 36 hours were recorded contemporaneously as part of standard care. Medical reasons were recorded awaiting medical review, stabilization, further evaluation, diagnostics, reversal of anticoagulation capacity, reasons related to the lack of operating theater capacity to control for case complexity. Patients delayed because of specialist surgical personnel or equipment requirements were excluded. So they're really trying to balance the cohort and they do some other things to balance the cohort as well. The exposure of interest was the time from ED presentation to surgery. And then in parentheses he used the word timely. Timely surgery was defined as initiation of the procedure 36 within 36 hours. Surgery was defined as capacity delayed when associated appropriately for capacity reasons. And the procedure is performed after this. So they do a couple of stepwise analyses, a multivariable analysis to identify factors affecting mortality as an initial step, followed by propensity scores to estimate the association of surgery within 36 hours as the exposure. They included a comprehensive number of covariates. Age, sex, preoperative hemoglobin, mental status, confusion, their residence before admission, comorbidities, malignancy within the previous 20 years. And they have a scoring system in the NHFS that includes these variables as well. And that's their rationalization for including them. So patients were matched one to one essentially to kind of get at the selection and indication bias around these like particular delays. And then they have a Cox model looking at the survival estimates. And then this is the part where it gets a little bit kind of you do it too much for just one study. But exploratory analysis of the low versus high risk patients and differences between the timely and delayed groups assessed using logistic regression to estimate odds ratios and then repeated using the frailty score to unpack that domain as well. They ended up including about 2,300 patients a shade over they had good mortality available. For all included cases, 46% received timely surgery, 54% experienced capacity related delay. That was quite surprising to me. Obviously nothing comparable to this that I'm aware of has been done in American medical centers, but I reasonably expect just on anecdotal experience that that number would be different in our system or our setting, but maybe not. [00:09:00] Speaker B: Depends on where you [00:09:01] Speaker C: work. Yeah, I guess do you see delays like that where you'd say shade over half or delayed beyond 30 seconds? [00:09:09] Speaker B: I'd be really interested. We have never looked at this separate from the medical delays and that's why I think this article is so uni. I really would be interested. When I was reading this, I was thinking, I'd love to see this data from our hospital for sure. In a health safety net environment, we have a lot of delays for the hip fractures. [00:09:23] Speaker C: So the capacity delay was seen with a greater hazard of mortality, 37% increase in the hazard, most pronounced over the course of the first 30 days. Shorter term mortality in patients with a higher clinical frailty score was most affected by the delay. So those with scores greater than four, while the effects on less frail patients were not significant. And this leads the authors to conclude that capacity related delays were associated with greater mortality after accounting for patient related risk factors. I mean, a delay is a delay, whatever the cause is that information, I think we know where. I think there really is unique value beyond the methodologic rigor, which is great, but methodologic rigor only goes so far when the conclusion just reinforces what you already expect. And we know the impact that delays have, but really where it comes through is the light that they're shedding on how you should triage to potentially minimize disparate impact. And that's really where the patients who have higher frailty should probably be going to the front of the line to ensure expedient surgery whenever possible because they have the least available reserves in which to tolerate these longer delays. And you really are talking about a sentinel event that can really alter the trajectory of individuals who were already frail and are essentially teetering on the edge, so to speak. So that's where I really think that this work, with excellent methodology and a very robust analytic approach, provides some really important insights that are immediately actionable and relevant to clinical practice. So a plus across the board on this one. [00:11:12] Speaker B: Yeah, I would agree. It [00:11:13] Speaker C: was really a good article. [00:11:14] Speaker B: I'd say the bottom line is, so when your case is on hold and it's a hip fracture, your patient's mortality risk is going up as the clock ticks. Which is why you should listen to only one podcast versus 36 consecutive podcasts in a row and get the front desk call for your patient already. So, next up we have incisional infiltration of liposomal bupivacaine in geriatric hip fracture surgery. A randomized parallel group trial. It's by you, there's a commentary. It's the lead article there is an infographic and it is 30 days free. Hip fracture volumes are rising due to the aging population. As we all know, an inadequate analgesia can impair recovery. Opioid medications can result in delirium and other detrimental effects in the frail population with hip fractures and so non opioid modalities for analgesia are really important. Liposomal bupivacaine is a local anesthetic designed to have a prolonged effect by way of encapsulating bupivacaine in multivesicular liposomes and it prolongs its release in the tissue in order to cover a 48 to 72 hour window after surgery. It has had mixed results in other orthopedic trials and so these authors sought to determine whether a local liposomal bupivacaine, if added to a multimodal analgesia regimen, confers any clinical benefit. It was a single center prospect of randomized trial. It was participant and assessor blinded in a parallel group of exploratory trial in older adults undergoing hemiarthroplasty or total hip arthroplasty for a hip fracture. The intervention was local liposomal bupivacaine infiltration. The control was no local infiltration. The primary endpoint was resting pain measured on a visual analog scale 0 to 10 at 48 hours postoperatively prespecified. Key secondary endpoints were early pain with activity, morphine, milligram equivalence or MME of the patient, controlled analgesia, PCA infusion volume, and the total perioperative oral and intramuscular rescue counts. They also measured sleep quality measured on a numeric rating scale NRS 0 10, total sleep time and nocturnal awakenings. Patients were 65 years and older, ASA classes 1 through 3, and they were randomized 1 to 1 to receive the liposomal liposomal bupivacaine or not. They, as mentioned, underwent a total hip or a hemiardoplasty, depending on indication. Intraoperative infiltration involved a 30cc injection containing 20ccs of the liposomal bupivacaine. For total hippar arthropathy. The liposomal bupivacaine was distributed in three equal portions of the capsule, the periarticular soft tissues, the deep muscles including the short external rotators, the gluteal musculature and the proximal iliotibial tract, and at the incision at wound closure. For hemiarythroplasty it was similar except not in the capsule, which is not clear why they differentiated between those two. It might be because they did a capsulectomy, but they didn't quite specify that all participants followed the same multimodal pathway, which included a supra inguinal fascia iliaca block containing 30ccs of 0.35% rapivacaine administered under ultrasound that was given 30 minutes per prior to the surgical incision, intravenous PCA containing sufentanil and they had pump logs capturing the infused volumes at 6, 8 and 24 hours and a rescue analgesia per prespecified thresholds. The primary outcome of resting pain at 48 hours there was no significant difference between the liposomal bupivacaine group and the control group. Resting pain, however, significantly favored the liposomal bupivacaine group at 24 hours, and there were benefits for several of the secondary outcomes, including activity related pain at 8 hours and 48 hours, as well as sleep quality and perioperative oral rescue analgesia, which was better in the liposomal bupivacaine group. The authors conclude that there are limited small early benefits to the use of liposomal bupivacaine in a robust multimodal protocol for improved activity pain related at some time points but with no effect on length of stay and no effect on functional recovery. So, you know, I would say the study limitations are that they they did not include a placebo or a control and the surgeons were not blinded. So there may be some performance bias and they mentioned this in their limitations. I think a more rigorous methodology would have had a comparison with a conventional bupivacaine or even a control placebo injection and have the surgeons blinded. The study was performed in Japan and may not be generalizable to other hip fracture programs. It included PCAs, which we don't rely on heavily in our practice, and it was in both groups. It's not a typical preference in the US due to potential opioids in this patient population for over sedation. And also they used a supra inguinal fascia iliaca block in all patients. It would be great if we could get that for all of our patients, but it's not typical in most programs because it requires highly specialized anesthesiologists that are trained in block regional anesthesia and that's not always available. We don't typically have that for all of our hip fractures here and so may not be necessarily generalizable to all practices. You know, I would say that it would be interesting to compare the liposomal bupivacaine to the block so to have a separate group that received the fascia Iliaca brox compared to the liposomal bupivacaine to see if we could potentially obviate the need for these specialty blocks. And I think another thing that would be an interesting outcome is the incidence of delirium or confusion in this group because that's a very specific potential detrimental problem in these patients postoperatively. And if we can minimize opioids and minimize the rescue analgesia with the liposomal bupivacaine, that's a potential benefit of this treatment. So I think overall it was a very well done study and I don't think it's on hold. I think it's a great study. What are your thoughts, Andrew? [00:17:04] Speaker C: Yeah, I mean, as far as randomized control trial go, it's great. Just a few kind of interesting points, not really critiques of the study itself, just sort of more philosophical, big picture concepts. We recently discussed a similar randomized controlled trial looking at multimodal therapies, where the authors were a little bit more vocal about we're so good at multimodal therapy, you can't see how great the intervention is. I was just struck by the fact that the primary endpoint, the median score for pain, was zero in both groups at 48 hours after surgery. I wouldn't say that that's like my own experience for patients here, 48 hours after surgery, that the average score is zero. So yeah, I mean, I think your points are well taken with respect to some of the impact that the baseline procedural efficacy. But you have to have some kind of margin to take up in terms of what the added benefit is going to be. You can't get better than zero. So if you already have something with zero, how can you really measure the efficacy of adding something else? And that's really where I think we get. And again, this is not a critique of this study. This is just philosophical where the randomized controlled trial paradigm sort of fails us in this context because of course it's the sine qua non of research, it's the gold standard of research. But when you power for a particular outcome, and I would say that, you know, in a case like this, where the outcome itself is not measurable by definition, you're probably underpowered, right? Like you didn't have enough patience with enough built in variation and you're not going to necessarily know that. So these are things where you have to have a larger population with a broader swath of individuals in terms of what's their baseline experience with pain, how do they articulate their pain, what are their pain Ratings. If you have a population of very. And again, I'm not talking about this patient population, I'm just speaking in general. If you have a population of very stoic patients who are not going to report pain for whatever reason, be it they. They themselves don't really experience it, they downplay it, they feel it's like a sign of weakness or something, you're not going to be able to measure this in a way that is translatable to other populations. I think there's room to repeat this study in maybe like a US cohort and the findings may be different. They do premise the narrative with. There have been a lot of studies on liposomal hivacaine, some in the spine space as well, and the results have been mixed. And I think that the mixed results probably tend to reflect the patient population in which they're being studied. If you have someone who has a very low pain tolerance or a low pain threshold or has had prior exposure to a lot of opioids for whatever reason, and therefore the conventional pain modalities that we use, such as oral medications, are not going to keep them comfortable, there may be real value in the liposomal bucket cane administration that you're not going to see that result in the rct. So I don't think you should condemn this intervention or say it's really not necessary. I think this is a very unique clinical context, as you pointed out, in which this work was being done. [00:20:46] Speaker B: Yeah, I think they kind of downplayed the impact of the liposomal bupivacaine because it did reduce rescue medication. And that's why I gotten to the point about the delirium. Because if you're reducing the rescue opioid, are they experiencing less side effects from those opioids? And that that actually would be very relev. Meaningful. And additionally sort of that it's maybe what they measured. I mean, their primary outcome measure was pain at rest. Most of these patients, you round on them 48 hours after their surgery and they're lying in bed, they're not in pain, they're in pain when they get up and move. Right. So I think the activity related pain is probably more of a meaningful primary outcome. But in any case, that's my thought. Good. [00:21:23] Speaker C: Yep. [00:21:24] Speaker B: So let's move on to our your cases on hold feature. We [00:21:28] Speaker C: haven't put anything on hold yet. [00:21:29] Speaker B: We haven't? No. It's all great papers. Your cases on hold feature at this issue is distal radius fracture as an early marker of bone fragility. A population based study in Japan by Shibata and colleagues. There is a commentary again, you don't have to take it from us. This is a retrospective cohort study from the Shizuoka Pardon me Kohuo database in Japan that was performed to evaluate how predictive a diagnosis of distal radius fracture is as a measure of broader systemic frailty and long term outcomes. The study used long term care claims of 2.4 million residents aged 65 to 89 who were newly diagnosed with a distal radius fracture from 2012 to 2022 compared to a control group, which is interesting, of upper limb contusion patients presenting for evaluation in which distal radius fracture was ruled out and who do not have a distal radius fracture and during the one year baseline period. The database contains information on demographics, diagnoses according to the ICD 10th revision procedures, prescriptions, long term care certifications and mortality. The study followed the strengthening of reporting of observational studies or the Strobe Reporting Guidelines. The Public LTC Insurance System or the Long Term Care Insurance System of Japan assigns care level on the basis of standardized assessments. The authors used baseline long term care certification as a proxy for functional status and dichotomized as non certified including support level versus certified levels. Care 1 through 5 and LTC deterioration was defined as the progression from a non certified or support status to any certified level during follow up. The primary outcome was all cause mortality based on insurance disenrollment records. The secondary outcomes included secondary fragility fractures, all cause hospitalization, LTC deterioration and osteoporosis. Treatment initiation Fragility fractures were defined using the ICD10 codes for common osteoporotic sites including the vertebra, hip, pelvis, proximal humerus and distal radius, and each outcome was independently assessed. Osteoporosis and its treatment were identified from claims records from medication class and adherence, but medication class, adherence and duration could not be reliably measured. The baseline characteristics including age, sex, comorbidities and the electronic frailty index or EFI were measured and the comorbidities included diabetes mellitus, any malignancy, myocardial infarction, renal disease and chronic pulmonary disease as well as cerebrovascular disease and anemia as well as rheumatoid arthritis. Propensity score matching was performed with a 1.111 nearest neighbor propensity score matching without replacement with a caliper of 0.1 and mortality was analyzed with Kaplan Meier survival curves. A causal mediation analysis was conducted to determine whether osteoporosis treatment initiation and secondary fracture occurrence mediated the effects of distal radius fracture on mortality. They found that the all cause mortality was actually lower in the fracture group compared to the non fracture group. Distal radius fracture was associated with lower mortality, but this was attenuated after multivariable adjustment that included baseline LTC status In the matched cohort. The fracture group had higher rates of all cause hospitalization and secondary distal radius hip fractures, lower leg fractures, vertebral compression fractures and pelvic fractures than the non fracture group. Initiation of osteoporosis treatment within one year after injury was more common in the fracture group. The main findings of the study were that long term outcomes after distal radius fracture depended on baseline functional status. They also found that distal radius fracture tended to occur in more physically active patients with preserved neuromuscular function whereby patients instinctively extend their arm. We all know the foosh when you land on your extended arm before you break your distal radius and they felt as though or they surmised that the fall on the outstretched hand requires intact gait, balance and reflexes. And they found that the contusion group, the non fracture group, actually had higher incidence of proximal humeral fractures and rib fractures. The authors hypothesized that the distal radius fracture mechanism of injury may represent preserved protective reflexes and higher baseline status, which I thought was very interesting. So while authors explain that their use of a trauma based group to avoid healthy user bias, I think there are some limitations with the choice of control. Number one is that the control group may have substantial variability. Patients with arm contusions could have any number of other traumatic injuries. They mentioned as an aside that they happen to have more proximal humerus and rib fractures, but what if they had more pelvic fractures and other fractures that we don't know about that that is a very variable control group that they have. So I would have been interested to see this group compared to perhaps a healthy cohort to see what the differences would be because it potentially introduces a whole host of other confounders in the control group and explains why the mortality differentials were quite small and may not have been specifically related to the presence or absence of a distal radius fracture. Another limitation was of course its retrospective claims based study and you know, there may be coding area error errors and missing information of other injuries. So that was my take, but I thought it was a very interesting study with some very important findings and I'm interested in your take specifically on as our stats guru on their stat strategies as well. [00:27:04] Speaker C: Yeah, no, absolutely. I was planning to weigh in on that so, yeah, I mean, obviously the first two studies were really great. This is, this is the one that I was quite a bit on the fence on and a little bit to the negative. I will say at the end, after careful consideration, I am going to put this case on hold for a couple reasons. The first is that they have like this proxy for frailty, this long term care designation. And the initial construct of the, the narrative is about they're presenting the study as a way to examine long term prognosis of older adults with a distal radius fracture, specifically focusing on all cause mortality, subsequent fractures and the LTC certification. Why is the study novel, you may ask? They say it's novel because they're integrating this LTC certification as a proxy for frailty. But there are other ways to measure frailty and you can. So this is a very much built around this LTC designation which is unique to this environment of care. Obviously we have things that might be comparable or analogous to some degree, but not necessarily the exact same thing. It's unique to the care system. And really the point for me that was the main, the main issue is what you already raised. You're taking a different type of patient that as you said and aptly pointed out, they could have other injuries just because they had a contusion. And they, I mean they even speak to that like this is a different type of patient. So making a comparison between someone who just sustained a distal radius fracture and someone who could have sustained a distal radius fracture but didn't, but was injured in other ways, that's not a good comparison. And I think we need to really center on again, coming back to the foundational premise that all of these studies are supposed to be experiments akin to what you could do in a lab. And if you were doing something in a lab where you have a certain set of a certain substrate and you're comparing that to something that's entirely different, even if you're randomizing them both, the experiment is going to fail or it's going to give you information that is not high quality and high yield. And I think that's really what the case is here. I think you would find different results. If you compare this population with distal radius fractures to a younger population that didn't have distal radius fractures, or even the same population that were certified as not needing any medical care beyond outpatient preventative services in the year prior, you'd get a totally different narrative. The reason that the distal radius fracture patients come out looking so good in this context is that you're Comparing them to people who had other more severe, potentially injuries. As much of a sentinel event as distal radius fracture may be, and I don't disagree that it should implicate and indicate as they do initiating osteoporosis treatment or workup to see if that's appropriate. What you're really trying to prevent are the life changing because of the impact on mobility and physical function. The hip fracture and multiple vertebral fractures, cumulative vertebral fractures and even rib fractures because of the impact on lung capacity can have outsized impacts on survival in a way that really the distal radius fracture doesn't. You can still walk around, you can still be independent ostensibly. And a lot of what they're presenting here in the discussion and their take home message is incredibly hypothetical, theoretical and essentially their discussion is almost entirely comprised of non sequiturs. This concept that if the distal radius fracture it's higher pre injury functional capacity, but that's only as compared to this other population that you put together. If, if I created this study with a control group of 40 year old women, then no, you're not going to be having a higher functional capacity pre injury. The idea that someone sustains a distal radius fracture, just the nature of that distal radius fracture itself is a harbinger of. You can just understand so much more about this patient. And their baseline functionality I think is. But it just doesn't line up to me. I mean if I had a patient who is non ambulatory at all and they fell out of bed and they land, they have a distal radius fracture, does that mean that these findings apply to them? No, of course not. They're non ambulatory. They're investing too much in what they've put together. Where there's so many artifacts in terms of the comparison group. And then talking about fractures, there's a critical window for initiating osteoporosis that, that goes back to the own to own the bone concepts which are more than 25 years old at this point in time. And so I would consider that a non sequitur. And then where they really lost me was where they talk about the distal radius fracture. There's not a protective effect of. I don't think I've ever conceptualized that having a fracture would afford you some type of. There's a protective effect of having a fracture. More patients should have more fractures so they'll live longer. I mean this is just such an erroneous attribution in the way that it's characterized in the text. And for those kind of three buckets. That's why I think this needs to be on hold. [00:33:13] Speaker B: Yeah, well that was very key. [00:33:14] Speaker C: You cannot call fractures a protective. There's not a protective effect for fractures. [00:33:18] Speaker B: No, absolutely not. Yeah. There's no silver lining really. [00:33:21] Speaker C: Right. There's no upside. [00:33:23] Speaker B: Yeah. Okay. So on hold. So next we will get into our honorable mentions. First we have edema enhanced CT derived from quantitative dual energy CT reduces experience related variability and sacral fragility Fracture diagnosis by ODA and colleagues. This study addresses the notion that sacral fractures are difficult to diagnose. The authors developed an edema enhanced CT EECT technique based on dual energy ct, which they acronymized as DECT and evaluated its diagnostic performance on sacral fractures. The study was performed in Japan. 50 patients with sacral fractures underwent single energy CT as well as a dual energy CT and an MRI on sagittal dual energy CT. The water equivalent density at the S1 vertebral midline was defined as the standard value or the sv in 16 regions of interest per patient. The relative standard value or RSV was calculated as the ratio relative to the SV and classified according to MRI findings. Receiver operating characteristic curves analyzed determine the optimal RSV cutoff for fracture detection and EECT images highlighted regions exceeding this threshold. Thirty patients were then independently assessed twice by orthopedic surgeons with less than three years or more than three years group A and group B respectively, of experience using single energy ct. They also had a group D that had the dual energy CT and E group with the EECT to evaluate fracture presence and localization. The findings for both fracture detection and localization was that the EECT showed the highest sensitivity, specificity and diagnostic accuracy, particularly for fracture site identification. Inter and intra observer reliability were also the highest for EECT and the performance gap between less experienced and experienced observers seen with the single energy CT was not observed when using the eect. So they concluded that the edema enhanced CT showed better performance than dual energy CT and single energy CT and sacral fracture detection and localization and it provided high accuracy and reliability regardless of observer experience and it could be very useful for sacral fractures. Next we have intraoperative bone quality assessments are reliable compared with opportunistic CT based Hounsfield unit measurements. This is by Lewis and associates. There is a commentary, a highlight, there is a visual summary and it is 30 days free. I thought this was a very cool and clever study performed to determine how accurately orthopedic surgeons can assess bone quality intraoperatively and whether the accuracy of surgeon evaluation varied based on anatomic location. When we stick our finger into the tibial plateau and there's smooshy bone we can say that it's great bone versus bad bone anyway. It was a prospective cross sectional study of an adult patients who underwent operative fat fracture fixation in a single level one trauma center and had associated CT data of their distal radius, femur, glenoid, lumbar spine, proximal tibia or calcaneus within six months of the day of surgery. They had seven board certified fellowship trained orthopedic surgeons document bone quality intraoperatively for all patients at the time of fracture fixation and they were blinded to the CT Hounsfield units. Surgeons rated the bone quality on a Likert scale from 1 to 10 where 1 was very poor, 5 was average and 10 was very high and additionally bone quality was evaluated categorically as osteoporotic, osteopenic or normal or could not be determined and patient characteristics including age, race, sex, location of injury and surgical procedure were collected. All patients had CT scans of one to six anatomic zones and to maximize accuracy and consistency, a single reviewer was blinded to the intraobserver bone quality assessments analyzed on all CTs. The average Hounsfield units were calculated using methods described by Schregner and associates using best fit circular interest or COI confined to the medullary bone and so of the 229 patients enrolled they had 215 available for CT data and were included in the study. The most common surgical sites were the femur, ankle and acetabulum and a positive linear relationship between hounds, full units and surgeon. Bone quality assessment was observed and was consistent across surgical anatomic sites. Abnormal bone quality was correctly identified by surgeon assessment with an 84% sensitivity and 97% specimens specificity. The study demonstrated that surgeons can reliably detect abnormal bone quality through intraoperative assessments across numerous surgical sites. Intraoperative assessments may provide an actionable and reliable feedback regarding bone density without additional cost or radiation in cases when opportunistic scans are not available. So there you have it. That is all we have for today's episode and we'll conclude episode 118. I hope you all have a great Thanksgiving and we will see you next time when Dr. Schoenfeld will be our host. Thanks everyone. [00:38:25] Speaker C: See you in December.

Other Episodes